Company News • Endpoint Arena

Mon, Jun 8, 2026

1 updates

2:30 PM

Lilly's oral GLP-1 Foundayo (orforglipron) delivered superior A1C control and weight loss in three pivotal type 2 diabetes trials

In ACHIEVE-3, Foundayo 17.2 mg drove 57.1% greater relative reduction in A1C and 73.6% greater relative weight loss compared to oral semaglutide 14 mg In ACHIEVE-2 and ACHIEVE-5, Foundayo delivered significant improvements in blood sugar and weight, with up to 68.6% and 69.1% of participants

Trial Results • Phase 3ACHIEVE program results Mon, Jun 8, 2026lilly.com

Sun, May 31, 2026

1 updates

LLY

8:01 AM

Lilly's Retevmo (selpercatinib) demonstrated an 83% reduction in the risk of disease recurrence or death as adjuvant therapy for people with early-stage RET fusion-positive lung cancer

Phase 3 LIBRETTO-432 results establish RET fusions alongside EGFR mutations and ALK fusions as biomarkers in early-stage lung cancer that are associated with dramatic treatment outcomes, underscoring the importance of comprehensive biomarker testing across all stages of disease These data will be

Trial Results • Phase 3LIBRETTO-432 EFS results Sun, May 31, 2026lilly.com

Thu, May 21, 2026

1 updates

LLY

6:45 AM

Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial

In TRIUMPH-1, participants on 12 mg retatrutide lost an average of 70.3 lbs (28.3%) over 80 weeks with 45.3% of participants achieving ≥ 30% weight loss, a level long associated with bariatric surgery Individuals with a baseline BMI ≥ 35 who participated in a study extension continued to lose

Trial Results • Phase 3Results event Thu, May 21, 2026lilly.com

Tue, May 12, 2026

1 updates

LLY

6:01 PM

Lilly's Foundayo and lower-dose Zepbound helped people maintain weight loss after switching from higher doses of injectable incretin therapy in two late-phase trials

In ATTAIN-MAINTAIN, participants who transitioned from a maximum tolerated dose (MTD) of Wegovy (semaglutide) to Foundayo maintained all but 0.9 kg of their previously achieved weight loss on average after one year In ATTAIN-MAINTAIN and SURMOUNT-MAINTAIN, participants who switched from Zepbound

Trial Results • Phase 3ECO presentation and publication Tue, May 12, 2026lilly.com

Tue, May 5, 2026

1 updates

LLY

6:45 AM

Lilly's Omvoh (mirikizumab-mrkz) is the first and only IL-23p19 to demonstrate durable disease clearance in ulcerative colitis through four years

In LUCENT-3, more than 60% of patients who achieved disease clearance at one year maintained it after four years of continuous Omvoh treatment Disease clearance is a high clinical bar in UC requiring simultaneous symptomatic, endoscopic and histologic remission INDIANAPOLIS, May 5, 2026

Trial Results • Phase 3lilly.com

Thu, Apr 16, 2026

1 updates

LLY

6:45 AM

ACHIEVE-4, the longest Phase 3 study of Lilly's Foundayo (orforglipron) to date, reaffirmed its cardiovascular and overall safety profile as well as consistent improvements across key measures of cardiometabolic health

In ACHIEVE-4, Foundayo met the primary objective of non-inferiority vs. insulin glargine with a 16% lower risk of MACE-4 events and a 23% lower risk of MACE-3 events In a pre-planned analysis, the risk of all-cause death was 57% lower for Foundayo vs.

Trial Results • Phase 3lilly.com

Mon, Apr 13, 2026

1 updates

LLY

6:45 AM

Lilly's Jaypirca (pirtobrutinib) significantly extended progression-free survival when added to a venetoclax time-limited regimen in patients with previously treated CLL/SLL

BRUIN CLL-322 is the first Phase 3 readout in CLL to utilize and outperform a venetoclax-containing control arm This trial predominantly enrolled a patient population previously treated with covalent BTK inhibitors, highly relevant to current practice These results mark the fourth positive Phase 3

Trial Results • Phase 3lilly.com